Research Triangle Park Latest News (North Carolina, United States)

Sam Searcy joins Elixia, a site management organization, to oversee and increase business growth.

A variety of factors are considered when healthcare providers (HCPs) speak upon which type 2 diabetes treatments in the clinical pipeline may be more disruptive and why.

Prescribing patterns come from a variety of factors for HCPs, but some are more important than others in the multiple sclerosis marketplace.

While healthcare providers are more familiar with multiple sclerosis therapies such as Evobrutinib, Ocrevus, and Kesimpta, there is a lot of new buzz and anticipation surrounding new MS drug treatments, according to newly published data by market...

Among branded ulcerative colitis treatments, 84% of US gastroenterologists expect Zeposia to see an increase in prescription volume over the next 12 months, according to new research on the ulcerative colitis marketplace published by Vivisum Partners.

New research into ulcerative colitis pipeline drugs found that US gastroenterologists who treat irritable bowel disease (IBD) have low awareness of some developing therapies.